152 related articles for article (PubMed ID: 31872768)
1. Dedifferentiated liposarcoma: when eribulin can make the difference.
Sbrana A; Paolieri F; Bloise F; Manacorda S; Nuzzo A; Sammarco E; Galli L; Falcone A
Future Oncol; 2020 Jan; 16(1s):21-24. PubMed ID: 31872768
[TBL] [Abstract][Full Text] [Related]
2. A case of eribulin-induced regression of liposarcoma of the left funiculus in a heavily pretreated patient.
Miano ST; Francini E; Petrioli R; Francini G
Future Oncol; 2020 Jan; 16(1s):33-38. PubMed ID: 31975628
[TBL] [Abstract][Full Text] [Related]
3. Experience with eribulin in pretreated patients with advanced liposarcoma: a case series.
Paioli A; Setola E; Palmerini E; Cesari M; Longhi A
Future Oncol; 2020 Jan; 16(1s):25-32. PubMed ID: 31858818
[TBL] [Abstract][Full Text] [Related]
4. Long-term eribulin treatment in patients with a single kidney and retroperitoneal liposarcoma.
Tober N; Gentile M; Iodice G
Future Oncol; 2020 Jan; 16(1s):5-8. PubMed ID: 31872769
[TBL] [Abstract][Full Text] [Related]
5. Delayed use of eribulin in a heavily pretreated liposarcoma patient, previously misdiagnosed as leiomyosarcoma.
Martorana F; Vigneri P; Manzella L; Tirrò E; Soto Parra HJ
Future Oncol; 2020 Jan; 16(1s):9-13. PubMed ID: 31916463
[TBL] [Abstract][Full Text] [Related]
6. Long-term treatment with eribulin in heavily pretreated women with metastatic breast cancer: a case series.
Morritti M; Iodice G; Melaccio A; D'Onofrio L; Bergnolo P; Boglione A; Comandone A; Molinaro P; Garigliano D
Future Oncol; 2017 Apr; 13(11s):25-33. PubMed ID: 28481183
[TBL] [Abstract][Full Text] [Related]
7. Eribulin rapidly reduces the aggressiveness of second primary breast cancer: a case report.
Falco I; Stragliotto S
Future Oncol; 2017 Apr; 13(11s):51-54. PubMed ID: 28481187
[TBL] [Abstract][Full Text] [Related]
8. Eribulin as an effective monotherapy in a chemo-pretreated woman with metastatic breast cancer: a case report.
Caputo R; Cianniello D; De Laurentiis M
Future Oncol; 2017 Apr; 13(11s):45-50. PubMed ID: 28481184
[TBL] [Abstract][Full Text] [Related]
9. Eribulin long-term response and rechallenge: report of two clinical cases.
Barbieri E; Rubino D; Hakim R; Fini A; Lenzi M; Zamagni C
Future Oncol; 2017 Apr; 13(11s):35-43. PubMed ID: 28481188
[TBL] [Abstract][Full Text] [Related]
10. Eribulin: an effective therapeutic option in liposarcoma.
Das M
Lancet Oncol; 2017 Oct; 18(10):e569. PubMed ID: 28890295
[No Abstract] [Full Text] [Related]
11. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial.
Schöffski P; Chawla S; Maki RG; Italiano A; Gelderblom H; Choy E; Grignani G; Camargo V; Bauer S; Rha SY; Blay JY; Hohenberger P; D'Adamo D; Guo M; Chmielowski B; Le Cesne A; Demetri GD; Patel SR
Lancet; 2016 Apr; 387(10028):1629-37. PubMed ID: 26874885
[TBL] [Abstract][Full Text] [Related]
12. Benefit of eribulin in a patient with HER2(+) breast cancer who progressed after trastuzumab and lapatinib: a case report.
Casanova C; Verlicchi A; Mazza V; Dazzi C
Future Oncol; 2015; 11(15 Suppl):9-15. PubMed ID: 26235259
[TBL] [Abstract][Full Text] [Related]
13. Eribulin in advanced liposarcoma and leiomyosarcoma.
Setola E; Noujaim J; Benson C; Chawla S; Palmerini E; Jones RL
Expert Rev Anticancer Ther; 2017 Aug; 17(8):717-723. PubMed ID: 28621163
[TBL] [Abstract][Full Text] [Related]
14. Eribulin across multiple lines of chemotherapy: a retrospective study on quality of life and efficacy in metastatic breast cancer patients.
Quaquarini E; Sottotetti F; D'Ambrosio D; Malovini A; Morganti S; Marinello A; Pavesi L; Frascaroli M
Future Oncol; 2017 Apr; 13(11s):11-23. PubMed ID: 28481185
[TBL] [Abstract][Full Text] [Related]
15. Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine.
Demetri GD; Schöffski P; Grignani G; Blay JY; Maki RG; Van Tine BA; Alcindor T; Jones RL; D'Adamo DR; Guo M; Chawla S
J Clin Oncol; 2017 Oct; 35(30):3433-3439. PubMed ID: 28854066
[TBL] [Abstract][Full Text] [Related]
16. Eribulin-based treatment in patients affected by sarcomas: a case series.
Grignani G; D'Ambrosio L
Future Oncol; 2020 Jan; 16(1s):1-3. PubMed ID: 31840540
[No Abstract] [Full Text] [Related]
17. Response to eribulin in a difficult-to-treat, heavily pretreated breast cancer patient: a case report.
Leo L; Caputo F; Sarno AD; Garofano T; Andreozzi F; Massaro MG; Montesarchio V
Future Oncol; 2015; 11(15 Suppl):27-30. PubMed ID: 26235262
[TBL] [Abstract][Full Text] [Related]
18. Response to eribulin in a patient with metastatic uterine leiomyosarcoma: a case report.
Aliberti S; Miano S; Tolomeo F; Merlini A; Aglietta M; Grignani G
Future Oncol; 2020 Jan; 16(1s):15-19. PubMed ID: 31916842
[TBL] [Abstract][Full Text] [Related]
19. Eribulin efficacy based on type of metastatic site: a real-life study in heavily pretreated metastatic breast cancer.
Prestifilippo A; Grippaldi D; Blanco G; Memeo L; Puliafito I; Giuffrida D
Future Oncol; 2017 Apr; 13(11s):5-10. PubMed ID: 28481186
[TBL] [Abstract][Full Text] [Related]
20. Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results.
Park YH; Kim TY; Im YH; Lee KS; Park IH; Sohn J; Lee SH; Im SA; Kim JH; Kim SH; Lee SJ; Koh SJ; Lee KH; Choi YJ; Cho EK; Lee S; Kang SY; Seo JH; Kim SB; Jung KH
Cancer Res Treat; 2017 Apr; 49(2):423-429. PubMed ID: 27488876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]